Welcome to Markets Desk, here's what's moving the needle right now.
Morgan Stanley's Mike Wilson is making the case that the S&P five hundred may actually need to pull back before it can push higher. The chief equity strategist says a correction could be healthy, and he's steering clients toward large-cap quality names — the kind of balance sheet strength that holds up when sentiment turns.
Shifting to healthcare, Novo Nordisk is out with real-world data showing patients who stepped up their Ozempic dose from one milligram to two milligrams saw a statistically significant six percent lower risk of major adverse cardiovascular events compared to Mounjaro users. That's not a clinical trial — it's real-world outcomes data, which carries its own weight with prescribers and investors alike.
And in private markets, EliseAI just closed a three hundred fifty million dollar round led by Andreessen Horowitz and Bessemer, valuing the company at four billion dollars — nearly double where it stood just over a year ago. The company automates back-office operations for landlords and health systems, and Ontario Teachers' Pension Plan came in as a new investor, which signals serious institutional conviction in AI-driven property tech.
That's the tape. Markets Desk, signing off the floor.
